|View printer-friendly version|
- Initial data from OpRegen® trial suggest cells able to engraft and survive at least 12 months
- Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months
“Through the quarter, we continued to execute on our plan with great
progress across all our programs within the
Third Quarter and Recent Accomplishments
OpRegen® (retinal pigment epithelial cells)
The ongoing Phase I/IIa clinical trial is evaluating the safety of
three different dosage regimens of OpRegen®
in the advanced form of dry age-related macular degeneration
(Dry-AMD). Dry-AMD is a condition for which there is currently no
FDA-approved therapy. Preliminary data from the first cohort of patients treated in this trial of OpRegen® resulted in no serious adverse events. Imaging data from the first patient who completed one-year of post-treatment clinical assessment may indicate that the graft can survive for at least 12 months. These and other data will be presented at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), on December 2, in Rome, Italy.
- Enrollment in the second cohort, in which patients are receiving a higher and more clinically meaningful 200,000 cell dose, is expected to be complete by year end 2016, and data are expected early in 2017.
- Additional data, from the third cohort, which is expected to commence before year end, is anticipated by the end of 2017.
- US clinical trial sites are expected to be announced in early 2017.
Renevia® (adipose cells + cell delivery matrix)
The Renevia® pivotal clinical trial
for HIV-related facial lipoatrophy continues to enroll new patients
and is on track to complete patient enrollment by the end of 2016. The
objective of the trial is to assess the safety and efficacy of Renevia® in
restoring normal skin contours in patients whose subcutaneous fat has
been lost due to antiviral drug treatment for HIV.
BioTimeexpects top-line efficacy data in the first half of 2017. If the data are positive, the company plans to submit an application for CE mark approval in Europe shortly thereafter.
- Positive data from the pivotal trial could provide support for future studies of Renevia® in certain broader applications of fat tissue deficits. These include various medical aesthetics applications, such as age-related and trauma-related facial fat loss.
AST-OPC1 (oligodendrocyte progenitor cells)
In September, BioTime’s affiliate
Asterias Biotherapeutics, Inc.(NYSE MKT: AST), announced positive data from the AST-OPC1 SCiSTAR Phase 1/2a clinical study in patients with complete cervical spinal cord injuries. All patients in the initial cohort who received 10 million AST-OPC1 cells showed at least one motor level of improvement (regaining some function in their arms), while two of five patients achieved two motor levels of improvement (regaining some function in their arms, hands and fingers) on at least one side of their body. The data were presented at the Annual Scientific Meeting of the International Spinal Cord Society(ISCoS) in Vienna, Austria.
Six-month efficacy data on this first cohort are expected to be
January 2017. Enrollment is also ongoing in a new cohort in which patients are receiving a higher dose of 20 million cells.
In August, BioTime’s subsidiary
OncoCyte Corporation(NYSE MKT: OCX) closed a financing with both new and existing investors, providing OncoCytewith gross proceeds of $10.55 million, before deducting placement agent fees and offering expenses.
Data was presented related to
OncoCyte'slead product, a confirmatory diagnostic for lung cancer screening. OncoCyteexpects to complete the study by year end and, if successful, could launch the product by mid-year 2017.
Research and Development
BioTimestrengthened its regenerative medicine intellectual property portfolio with the issuance of 31 new patents. This included nine in the U.S. and 22 in Australia, Canada, China, India, Israel, and Japan. The new patents supplement the existing portfolio of more than 700 patents and patent applications owned or licensed by the BioTimefamily of companies worldwide.
BioTimestrengthened its senior management team with the appointment of Jim Knightas Senior Vice President, Head of Corporate Development. Mr. Knight is a highly accomplished professional with an extensive skill set and knowledge that is applicable immediately, as the company has started reporting encouraging early clinical data on its key programs.
Third Quarter Financial Results
Cash Position and Equity Values: Cash and cash equivalents
totaled $30.5 million as of September 30, 2016, compared to $42.2
million as of December 31, 2015, which included Asterias’ cash and cash
equivalents of $11.2 million. Based on the
Revenues: Total revenues were $1.5 million for the third quarter, compared to $2.3 million in the third quarter of 2015. Asterias’ total revenues included in the third quarter of 2015 were $1.4 million as shown in the table below (in thousands). BioTime’s operating revenues are currently generated primarily from research grants, licensing fees and advertising from the marketing of online database products.
|Three months ended September 30, 2016||Three months ended September 30, 2015|
R&D Expenses: Research and development expenses were $6.4
million for the third quarter, compared to $11.4 million for the
comparable period in 2015. The 2015 expenses included $4.6
million attributable to Asterias' research and development. The decrease
year over year was primarily due to the deconsolidation of Asterias for
financial reporting purposes commencing
G&A Expenses: General and administrative expenses were $4.6
million for the third quarter, compared to $7.5 million for the third
quarter of 2015. The decrease was primarily due to the deconsolidation
of Asterias financial results and reduced expenses incurred by
Operating Loss: Loss from operations was
Net Income (loss) attributable to BioTime: Net income
attributable to BioTime was $31.2 million, or
Conference Call and Webcast Details
A replay of the conference call will be available for seven business
days beginning about two hours after the conclusion of the live call, by
calling toll-free from U.S./
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime, Inc. specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
BIOTIME, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||30,451||$||42,229|
|Available for sale securities||903||753|
|Trade accounts and grants receivable, net||1,604||1,078|
|Prepaid expenses and other current assets||2,079||2,610|
|Total current assets||35,152||47,237|
|Property, plant and equipment, net and construction in progress||4,726||7,539|
|Deferred license fees||145||322|
|Deposits and other long-term assets||1,011||1,299|
|Equity method investment in Asterias, at fair value||92,210||-|
|Equity method investment in Ascendance||3,482||4,671|
|Intangible assets, net||10,848||33,592|
|LIABILITIES AND SHAREHOLDERS' EQUITY|
|Accounts payable and accrued liabilities||$||7,176||$||9,377|
|Capital lease liability, current portion||173||38|
|Promissory notes, current portion||95||95|
|Related party convertible debt, net of discount, current portion||357||-|
|Deferred grant income||-||2,513|
|Deferred license and subscription revenue, current portion||537||439|
|Total current liabilities||8,338||12,462|
|Deferred revenues, net of current portion||385||615|
|Deferred rent liabilities, net of current portion||46||158|
|Related party convertible debt, net of discount, net of current portion||954||324|
|Promissory notes, net of current portion||173||220|
|Capital lease, net of current and other liabilities||89||34|
|Commitments and contingencies|
|Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding||-||-|
|Common shares, no par value, 150,000 shares authorized; 103,392 shares issued and 102,772 shares outstanding at September 30, 2016; 94,894 issued and 90,421 outstanding at December 31, 2015||313,506||274,342|
|Accumulated other comprehensive loss||(690||)||(237||)|
|Treasury stock at cost: 620 shares at September 30, 2016 and 4,473 shares at December 31, 2015||(2,891||)||(18,033||)|
|BioTime, Inc. shareholders' equity||119,391||26,891|
|Total shareholders' equity||136,241||76,447|
|TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY||$||147,574||$||94,660|
BIOTIME, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Three Months Ended
Nine Months Ended
|Royalties from product sales and license fees||177||357||463||631|
|Subscription and advertisement revenues||69||343||700||1,020|
|Sale of research products and services||144||140||331||328|
|Cost of sales||(58||)||(432||)||(378||)||(957||)|
|Research and development||(6,422||)||(11,433||)||(29,093||)||(29,816||)|
|General and administrative||(4,574||)||(7,545||)||(23,083||)||(18,911||)|
|Total operating expenses||(10,996||)||(18,978||)||(52,176||)||(48,727||)|
|Loss from operations||(9,555||)||(17,104||)||(47,714||)||(44,109||)|
|Interest income/(expense), net||(167||)||(12)||(513||)||(207||)|
|BioTime’s share of losses in equity method investment in Ascendance||(855||)||-||(1,189||)||-|
|Gain on deconsolidation of Asterias||-||-||49,048||-|
Gain on equity method investment in Asterias at fair value
|Other income/(expense), net||
|Total other income/(expense), net||38,820||
|INCOME (LOSS) BEFORE INCOME TAX BENEFIT||29,265||(17,689||)||26,361||(44,724||)|
|Deferred income tax benefit||-||948||-||3,395|
|NET INCOME (LOSS)||29,265||(16,741||)||26,361||(41,329||)|
|Net loss attributable to non-controlling interest||1,934||3,115||12,286||7,762|
|NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.||31,199||(13,626||)||38,647||(33,567||)|
|Dividends on preferred shares||-||(363||)||-||(415||)|
|NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS||31,199||(13,989||)||38,647||(33,982||)|
|NET INCOME (LOSS) PER COMMON SHARE:|
|WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:|